e-learning
resources
Virtual 2021
06.09.2021
Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Analysis of patients with interstitial lung disease associated to Systemic Sclerosis treated with cyclophosphamide.
L. Arreguy Nogueira (Belo Horizonte (MG), Brazil), E. Mancuzo (Belo Horizonte (MG), Brazil)
Source:
Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Session:
Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Session type:
E-poster
Number:
2341
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Arreguy Nogueira (Belo Horizonte (MG), Brazil), E. Mancuzo (Belo Horizonte (MG), Brazil). Analysis of patients with interstitial lung disease associated to Systemic Sclerosis treated with cyclophosphamide.. 2341
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy
Source: International Congress 2014 – ILDs 4
Year: 2014
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
Assessment of disease progression in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients using Functional Respiratory Imaging (FRI)
Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update
Year: 2019
Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis
Source: International Congress 2014 – Sarcoidosis
Year: 2014
Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment
Source: International Congress 2016 – Orphan diseases I
Year: 2016
High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Interstitial lung disease associated with polymyositis-dermatomyositis
Source: Eur Respir J 2005; 26: Suppl. 49, 31s
Year: 2005
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Interstitial lung disease in systemic sclerosis: where do we stand?
Source: Eur Respir Rev 2015; 24: 411-419
Year: 2015
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept